Suzanne Crowe
Known title: DirectorCIK: 0001816242
Suzanne Crowe's purchase track record
Suzanne Crowe has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/9/2024 | RCEL | $6K | -39.3% | -55.4% | -0.8% |
| 9/20/2021 | RCEL | $18K | -30.7% | -54.5% | +2.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| RCEL | ▲ Buy | Grant | 22,214 | — | 1/20/2026 | View on chart |
| RCEL | ▲ Buy | Grant | 10,022 | — | 1/21/2025 | View on chart |
| RCEL | ▲ Buy | Open Market | 486 | $6K | 12/9/2024 | View on chart |
| RCEL | ▲ Buy | Grant | 9,200 | — | 6/5/2024 | View on chart |
| RCEL | ▲ Buy | Grant | 6,175 | — | 6/6/2023 | View on chart |
| RCEL | ▲ Buy | Grant | 12,589 | — | 12/12/2022 | View on chart |
| RCEL | ▲ Buy | Grant | 4,350 | — | 12/22/2021 | View on chart |
| RCEL | ▲ Buy | Open Market | 1,066 | $18K | 9/20/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
RCEL Gains Fair Value Lift After PermeaDerm Data and Q2 Beat
PermeaDerm data and a Q2 earnings beat lifted RCEL’s fair value. The news gave the stock a positive momentum boost. The lift comes as the company reports stronger‑than‑expected results and promising data from its PermeaDerm platform. The move is a short‑term reaction to the earnings beat and data release.
RCEL Gains Fair Value Lift After PermeaDerm Data and Q2 Beat. PermeaDerm data and a Q2 earnings beat lifted RCEL’s fair value. The news gave the stock a positive momentum boost. The lift comes as the company reports stronger‑than‑expected results and promising data from its PermeaDerm platform. The move is a short‑term reaction to the earnings beat and data release.